pazopanib + irinotecan + temozolomide

The PAZIT regimen is a combination therapy consisting of the multi-kinase inhibitor pazopanib, the topoisomerase I inhibitor irinotecan, and the alkylating agent temozolomide. This combination was specifically evaluated by the University of California, San Francisco (UCSF) in a Phase 1 clinical trial (NCT03139331) for pediatric and young adult patients with relapsed or refractory sarcomas. Pazopanib, a small molecule tyrosine kinase inhibitor, targets several receptors involved in tumor angiogenesis and growth, including VEGFR, PDGFR, and c-Kit. Irinotecan is a cytotoxic chemotherapy that prevents DNA religation by inhibiting topoisomerase I, while temozolomide is an oral alkylating agent that delivers a methyl group to DNA, leading to cell death. The trial aimed to determine the safety and maximum tolerated dose of this triple-drug combination in advanced sarcoma cases, though initial results indicated significant dose-limiting toxicities.

Other names

PAZIT regimenPazopanib with Irinotecan and Temozolomide